复星医药：斯鲁利单抗注射液上市许可申请获EMA收礼，目前处于审评阶段

每日经济新闻08-15

每经AI快讯，有投资者在投资者互动平台提问：2023年3月23日，公司自主研发的抗PD-1单抗斯鲁利单抗（H药，中国商品名：汉斯状®）联合化疗一线治疗广泛期小细胞肺癌（ES-SCLC）的上市许可申请（MAA）获欧洲药品管理局（EMA）受理。至今过去一年多，进展如何，请问在三季度能获批吗？复星医药（600196.SH）8月15日在投资者互动平台表示，斯鲁利单抗注射液（中国境内商品名：汉斯状）联合化疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2459448356?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-15 17:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2459448356","market":"sh","top_or_hot":-1,"title":"复星医药：斯鲁利单抗注射液上市许可申请获EMA收礼，目前处于审评阶段","media":"每日经济新闻","content":"<div>\n<p>每经AI快讯，有投资者在投资者互动平台提问：2023年3月23日，公司自主研发的抗PD-1单抗斯鲁利单抗（H药，中国商品名：汉斯状®）联合化疗一线治疗广泛期小细胞肺癌（ES-SCLC）的上市许可申请（MAA）获欧洲药品管理局（EMA）受理。至今过去一年多，进展如何，请问在三季度能获批吗？复星医药（600196.SH）8月15日在投资者互动平台表示，斯鲁利单抗注射液（中国境内商品名：汉斯状）联合化疗...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815170358959aefd5&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药：斯鲁利单抗注射液上市许可申请获EMA收礼，目前处于审评阶段</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药：斯鲁利单抗注射液上市许可申请获EMA收礼，目前处于审评阶段\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-15 17:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815170358959aefd5&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>每经AI快讯，有投资者在投资者互动平台提问：2023年3月23日，公司自主研发的抗PD-1单抗斯鲁利单抗（H药，中国商品名：汉斯状®）联合化疗一线治疗广泛期小细胞肺癌（ES-SCLC）的上市许可申请（MAA）获欧洲药品管理局（EMA）受理。至今过去一年多，进展如何，请问在三季度能获批吗？复星医药（600196.SH）8月15日在投资者互动平台表示，斯鲁利单抗注射液（中国境内商品名：汉斯状）联合化疗...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815170358959aefd5&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815170358959aefd5&s=b","article_id":"2459448356","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815170358959aefd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2459448356","pubTimestamp":1723712592,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"至今过去一年多，进展如何，请问在三季度能获批吗？复星医药8月15日在投资者互动平台表示，斯鲁利单抗注射液联合化疗一线治疗广泛期小细胞肺癌的上市许可申请于2023年3月获得欧洲药品管理局受理，目前处于审评阶段，获得上市许可的时间和结果均具有不确定性。公司将持续推进该产品的全球商业化布局，提升产品的可及性。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0175":"白马股","BK0188":"融资融券","BK0096":"民营医院","BK0028":"国家队","BK0060":"抗癌","BK0187":"一线龙头","BK0183":"MSCI概念","BK0012":"证金概念","BK0239":"医药制造","BK0196":"行业龙头"},"translate_title":"Fosun Pharma: The application for marketing authorization of serulimab injection was accepted by EMA and is currently in the review stage","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1},"content_text":"每经AI快讯，有投资者在投资者互动平台提问：2023年3月23日，公司自主研发的抗PD-1单抗斯鲁利单抗（H药，中国商品名：汉斯状®）联合化疗一线治疗广泛期小细胞肺癌（ES-SCLC）的上市许可申请（MAA）获欧洲药品管理局（EMA）受理。至今过去一年多，进展如何，请问在三季度能获批吗？复星医药（600196.SH）8月15日在投资者互动平台表示，斯鲁利单抗注射液（中国境内商品名：汉斯状）联合化疗一线治疗广泛期小细胞肺癌（ES-SCLC）的上市许可申请（MAA）于2023年3月获得欧洲药品管理局（EMA）受理，目前处于审评阶段，获得上市许可的时间和结果均具有不确定性。公司将持续推进该产品的全球商业化布局，提升产品的可及性。(记者 张喜威)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459448356"}